Table 3 The association of antiplatelet drugs with VAF for AVG
From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
| Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development | Number of Bleeding events (Control) |
|---|---|---|---|---|---|---|
| Harter et al [66] | Placebo-controlled | 44 (NA) |
Aspirin 160 mg/day NA | AVG thrombosis (5 months) |
Lower risk (32% vs. 72%, P < 0.01) | NA |
| Sreedhara et al [65] | Placebo-controlled | 53 (24) |
Dipyridamole 225 mg 3× /day Pre | AVG thrombosis (18 months) |
Lower risk (42% vs. 80%, RR 0.35, P = 0.02) |
2 (5) NS |
| Kaufman et al [64] | Placebo-controlled | 200 (96) |
Clopidogrel 75 mg/day + Aspirin 325 mg/day Post | AVG thrombosis (stopped by bleeding risk) |
Equivalent risk (HR 0.81, 95% CI 0.47–1.40, P = 0.45) |
38 (67) P = 0.006 |
| Trimarchi et al [63] | Placebo-controlled | 19 (8) |
Clopidogrel 75 mg/day Post | Time to AVG thrombosis |
Lower risk (350 vs. 86 days, P < 0.001) | None |
| Dixon et al [61] | Placebo-controlled | 649 (328) |
Dipyridamole 400 mg 2× /day + Aspirin 50 mg 2× /day Post | Primary patency rates of AVG (4.5 years) |
Lower risk (HR 0.82, 95% CI 0.68–0.98, P = 0.03) |
40 (37) NS |